Cantor Fitzgerald has begun coverage of Eli Lilly (LLY, Financial) with a favorable outlook, assigning an Overweight rating and setting a price target of $975. This announcement points to a strong start for the company in 2025, underscored by positive data from the ACHIEVE-1 trial for orforglipron and advancements in their GLP-1 commercial operations.
The company's diabetes treatment, Mounjaro, is maintaining significant growth momentum and is closing in on the popularity levels of the competitor drug, Ozempic. Cantor Fitzgerald highlights that Eli Lilly could command more than 85% of the obesity market by the end of the decade as new competitors emerge.
This strategic positioning suggests a promising future for Eli Lilly, driven by its innovative product lineup and market leadership aspirations. Investors are advised to keep an eye on LLY as it advances its market presence and continues to build on its recent successes.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 25 analysts, the average target price for Eli Lilly and Co (LLY, Financial) is $1,016.05 with a high estimate of $1,190.00 and a low estimate of $800.00. The average target implies an upside of 24.21% from the current price of $818.02. More detailed estimate data can be found on the Eli Lilly and Co (LLY) Forecast page.
Based on the consensus recommendation from 29 brokerage firms, Eli Lilly and Co's (LLY, Financial) average brokerage recommendation is currently 1.9, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Eli Lilly and Co (LLY, Financial) in one year is $1126.67, suggesting a upside of 37.73% from the current price of $818.02. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Eli Lilly and Co (LLY) Summary page.
